Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Vaxcyte, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 126 | 198 | +72 |
| Shares | 56.5M | 81.6M | +25.1M (+44.4%) |
| Value | $1.36B | $3.91B | +$2.55B (+188.4%) |
New holders (82)
Institutions that held Vaxcyte, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (10)
Institutions that held Vaxcyte, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Endurant Capital Management LP | 52,309 | $1.25M |
| Algert Global LLC | 45,505 | $1.09M |
| Martingale Asset Management L P | 33,513 | $806.0K |
| Temasek Holdings (Private) Ltd | 27,272 | $654.5K |
| Penn Mutual Asset Management, LLC | 15,585 | $374.0K |
| Chicago Partners Investment Group LLC | 6,402 | $278.0K |
| Balyasny Asset Management LLC | 9,417 | $226.0K |
| Amundi | 2,604 | $62.0K |
| Macquarie Group Ltd | 0 | $22.0K |
| Bell Investment Advisors, Inc | 28 | $1.00K |